Aspire Biopharma

Aspire Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative formulations of established drugs to improve patient outcomes in emergency and acute care settings. The company's flagship product, Aspri, is a proprietary liquid formulation of aspirin designed for rapid absorption, specifically targeting the treatment of acute myocardial infarction (AMI) and stroke. By utilizing the 505(b)(2) regulatory pathway, Aspire aims to provide a faster-acting alternative to traditional solid-dose aspirin, which can be difficult to administer and slow to absorb during cardiovascular emergencies. The company is also exploring the application of its formulation technology for broader indications in pain and inflammation. Headquartered in the United States, Aspire Biopharma leverages its leadership's extensive experience in drug delivery and commercialization to address critical gaps in current therapeutic regimens.